Evolution of RAS testing over time: factors influencing mutation rates in metastatic colorectal cancer patients

A. Lièvre, Des mutations de KRAS aux mutations de RAS : vers une meilleure définition de la réponse aux anticorps anti-EGFR dans le cancer colorectal métastatique Oncologie. ,vol. 16, pp. 120- 128 ,(2014) , 10.1007/S10269-014-2376-4

Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit, Sultan Eser, Colin Mathers, Marise Rebelo, Donald Maxwell Parkin, David Forman, Freddie Bray, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. ,vol. 136, ,(2015) , 10.1002/IJC.29210

F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685

Edith P. Mitchell, Targeted therapy for metastatic colorectal cancer: role of aflibercept. Clinical Colorectal Cancer. ,vol. 12, pp. 73- 85 ,(2013) , 10.1016/J.CLCC.2012.08.001

Chen Mao, Ru-Yan Liao, Li-Xin Qiu, Xi-Wen Wang, Hong Ding, Qing Chen, BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. Molecular Biology Reports. ,vol. 38, pp. 2219- 2223 ,(2011) , 10.1007/S11033-010-0351-4

Richard M Goldberg, Advances in the treatment of metastatic colorectal cancer. American Journal of Therapeutics. ,vol. 16, pp. 412- 420 ,(2009) , 10.1097/MJT.0B013E3181907ED9

Lydia G. M. van der Geest, Jorine’t Lam-Boer, Miriam Koopman, Cees Verhoef, Marloes A. G. Elferink, Johannes H. W. de Wilt, Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases Clinical & Experimental Metastasis. ,vol. 32, pp. 457- 465 ,(2015) , 10.1007/S10585-015-9719-0

Jean-Yves Douillard, Kelly S Oliner, Salvatore Siena, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, Gyorgy Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocákova, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean Luc Canon, Mark Rother, Richard Williams, Alan Rong, Jeffrey Wiezorek, Roger Sidhu, Scott D Patterson, None, Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer The New England Journal of Medicine. ,vol. 369, pp. 1023- 1034 ,(2013) , 10.1056/NEJMOA1305275

Fritz Wrba, Regina Knittelfelder, Elisabeth Lindner, Christoph C. Zielinski, Berthold Streubel, Thomas Brodowicz, Klaus Kaczirek, Tudor E. Ciuleanu, Damir Vrbanec, Erika Marton, Diethelm Messinger, Bernadette Liegl-Atzwanger, FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study Clinical Colorectal Cancer. ,vol. 14, pp. 91- 98 ,(2015) , 10.1016/J.CLCC.2014.12.003

W. De Roock, H. Piessevaux, J. De Schutter, M. Janssens, G. De Hertogh, N. Personeni, B. Biesmans, J.-L. Van Laethem, M. Peeters, Y. Humblet, E. Van Cutsem, S. Tejpar, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Annals of Oncology. ,vol. 19, pp. 508- 515 ,(2008) , 10.1093/ANNONC/MDM496